Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The grant is designated for the research and development of Pyronaridine
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
